|
|
Peptide-drug conjugates (PDCs) have emerged as a promising class of targeted
therapeutics. Structurally similar to ADCs, PDCs differ in their homing device,
offering unique advantages. A typical PDC is consists of three essential
components: a homing peptide, a linker and a cytotoxic payload (Fig 1). The
homing peptide includes targeting peptides and cell-penetrating peptides to
guide the drug to its intended site. This structure design enables enhanced cell
penetration, Reduced immunogenicity and
cost-effective synthesis[1]. |
|
|
| Figure 1. A schematic structure of peptide–drug conjugates[1]. |
While only a few PDCs, such as 177Lu-DOTATATE and 177Lu-PSMA-617, have gained approval, most
remain in clinical development. Key challenges such as drug stability, efficacy,
and administration methods require further optimization to expand therapeutic
application, particularly in cancer treatment. |
 |
MedChemExpress: Your Partner in PDC Research |
|
MedChemExpress provides a comprehensive range of custom services and products
tailored to support your PDC research needs. |
| Product Service |
Description |
XDC custom service
|
One-stop custom services for ADCs, PDCs, POCs, XDC
linkers, and more. |
Peptide custom service
|
Custom synthesis for linear peptides, cyclic peptides,
fluorescent peptides, and peptide-chelator conjugates. |
| Product Name |
Description |
Cyclo(RGDyK)
|
A potent and selective αvβ3 integrin inhibitor. |
Angiopep-2 hydrochloride
|
A brain peptide vector for conjugation with anticancer
agents, ideal for brain cancer research. |
7-O-(Amino-PEG4)-paclitaxel
|
A Paclitaxel-linker conjugate for XDC synthesis. |
DOTATATE
|
A DOTA-conjugated peptide for PET imaging and peptide
receptor radionuclide research. |
|
|
| Reference: |
| [1] Chem Soc Rev. 2021 Feb 15;50(3):1480-1494. |
|
|
|
|
|
|
Products are for research use only and are not intended for human use. We do
not sell to patients.
|
|
|
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
